Mimedx (MDXG) EBITDA Margin (2011 - 2026)

Mimedx has disclosed EBITDA Margin across 16 years of filings, most recently posting 28.69% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 4124.0% year-over-year to 28.69%; the TTM figure through Jun 2026 stood at 2.46% (down 931.0% YoY), while the FY2025 annual figure was 15.26%, down 161.0% from the prior year.
• EBITDA Margin came in at 28.69% for Q2 2026 at Mimedx, down from 27.21% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 26.89% in Q2 2024 to a low of 28.69% in Q2 2026.
• Average EBITDA Margin over 5 years is 4.99%, with a median of 12.91% recorded in 2025.
• Year-over-year, EBITDA Margin jumped 2775 bps in 2023 and slumped 4124 bps in 2026.
• Over 5 years, EBITDA Margin stood at 15.21% in 2022, then climbed by 17 bps to 17.84% in 2023, then plunged by 33 bps to 11.9% in 2024, then surged by 50 bps to 17.85% in 2025, then slumped by 261 bps to 28.69% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 28.69% in Q2 2026, 27.21% in Q1 2026, and 17.85% in Q4 2025.